GlassScriptPhysician profile
Ramon M Deleon
NPI 1750305561
$7,824.38
in general payments reported to CMS, 2019-2025
48 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $1,103 · 2021: $1,163 · 2022: $1,482 · 2023: $886 · 2024: $923 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.39 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,023.44 | 2019-2022 | |
| Amgen INC. | $996.18 | 2019-2025 | Tepezza, Repatha, Evenity |
| Boston Scientific Corporation | $736.44 | 2019-2024 | Watchman Flx, Watchman Access System |
| Abbvie INC. | $562.19 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $527.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $405.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $357.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $308.25 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Cleerly, INC. | $307.58 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Bayer Healthcare Pharmaceuticals INC. | $237.53 | 2022-2024 | |
| Amarin Pharma, INC. | $209.97 | 2019-2022 | |
| Glaxosmithkline, LLC. | $198.66 | 2019-2021 | |
| Nevro Corp. | $161.78 | 2024 | Senza |
| Lilly USA, LLC | $148.91 | 2021-2024 | Mounjaro, Zepbound, Baqsimi |
| Novartis Pharmaceuticals Corporation | $148.56 | 2019-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.